Published: 2019-09-25

A study of prevalence of metabolic syndrome in patients with type 2 diabetes mellitus in a tertiary care referral hospital in West Bengal

Tamoghna Maiti, Sonai Mandal, Ratul Banerjee, Somenath Das, Amrita Panda


Background: The terms "metabolic syndrome", "insulin resistance syndrome" and "syndrome X" are now used specifically to define a constellation of abnormalities that is associated with increased risk for the development of type 2 diabetes and atherosclerotic vascular disease. It is a state of chronic low grade inflammation with the profound systemic effects. Several organisations gave several criteria to diagnose it. Effective preventive approaches include lifestyle changes, primarily weight loss, diet, and exercise, the appropriate use of pharmacological agents to reduce the specific risk factors.

Methods: A cross-sectional study was done to evaluate the co-morbidity profile of patients, with metabolic syndrome and correlate clinical manifestations with specific components or metabolic syndrome, at the OPD of Bankura Sammilani Medical College and Hospitals, West Bengal. American Association of Clinical Endocrinologists criteria were chosen for diagnosis.

Results: 100 patients were recruited having type II diabetes mellitus. Most of the patients were male between 20-70 years and maximum was on oral hypoglycemic agent with app 40% patient was without any glycemic control. In comorbidities hypertension was highest, followed by coronary artery disease, hypothyroidism and cerebrovascular accident. Waist-hip ratio was highest in female. All of the patients were having some cardiac risk factor assessed by ECG, echocardiography and thread mill test.

Conclusions: The data demonstrates that metabolic syndrome is extremely common among diabetic patients. Frequency was much higher in women than men. Obesity is a key element in causing the metabolic syndrome and this factor was also more common in women.


Metabolic syndrome, Type 2 diabetes, Cardiovascular risk

Full Text:



Joslin EP. The prevention of diabetes mellitus. JAMA. 1921;76:79-84.

Kylin E. Studies of the hypertension-hyperglycemia-hyperuricemia syndrome (German). Zentralbl Inn Med. 1923;44:105-27.

Phillips GB. Relationship between serum sex hormones and glucose, insulin, and lipid abnormalities in men with myocardial infarction. Proc Nail Acad Sci USA. 1977;74:1729-33.

Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-607.

Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National heart, lung, and blood institute; American heart association; World heart federation; International atherosclerosis society; And international association for the study of obesity. Circulation. 2009;120(16):1640-5.

Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract. 2014;2014:943162.

Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. The Lancet. 2005;365(9468):1415-28.

Wong ND. Intensified screening and treatment of the metabolic syndrome for cardiovascular risk reduction. Preventive Cardiol. 2005;8(1):47-54

Deen D. Metabolic syndrome: time for action. The Am Family Physician. 2004;69(12):2875-87.

Wilson PWF, Grundy SM. The metabolic syndrome practical guide to origins and treatment: part I. Circulation. 2003;108(12):1422-4.

National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult treatment panel III) final report. Circulation. 2002;106(25):3143-421.

Eidelman RS, Hebert PR, Weisman SM, Hennekens CH. An update on aspirin in the primary prevention of cardiovascular disease. Arch Internal Med. 2003;163(17):2006-10.

Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004:27:1047-53.

Gupta R, Deedwania PC, Gupta A, Rastogi S, Panwar RB, Kothari K. Prevalence of metabolic syndrome in an Indian urban population. Int J Cardiol. 2004:97:257-61.

Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med. 2004;164:1066-76.

Desalu OO, Salami AK, Oluboyo PO, Olarinoye JK. Prevalence and socio-demographic determinants of obesity among adults in an urban Nigerian population. Sahel Med J. 2008;11:61-4.

WHO Non-Communicable Disease Country Profiles. Available at: Accessed on 10 November 2014.

Lovejoy JC. The influence of sex hormones on obesity across the female life span. J Womens Health. 1998;7:1247-56.

Bruno G, Merletti F, Biggeri A, Bargero G, Ferrero S, Runzo C, et al. Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: The Casale Monferrato study. Diabetes Care. 2004;27:2689-94.

Foucan L. Deloumeaux J, Donnet JP, Bangou J, Larifla Messerchmitt C, Salmi LR, Kangambega P. Metabolic syndrome components in Indian migrants with type 2 diabetes. A matched comparative study. Diabetes Metab. 2006;32:337-42.

A population-based study. Risk Factor and Life Expectancy Research Group. Am J Epidemiol. 1998;148:958-66.